Suzhou Institute for Biomedical Research (SZIBR) dedicated to developing the next generation of medicines accelerated by world-class drug discovery and development capabilities. As a biomedical research hub, SZIBR’s research interests approach a broad range of human diseases, including cancer, metabolic and cardiovascular diseases, infectious and neglected diseases etc. SZIBR is bridging the gap between academia and industry, establishing a symbiotic relationship that has led to innovative research and commercialization.